International Archives of Allergy and Immunology
Original Paper
Effects of Mizolastine in vitro on Human Immunocompetent and Airway Cells: Evidence for Safety and Additional PropertyOddera S.a · Cagnoni F.a · Dellacasa P.b · Canonica G.W.aaAllergy and Respiratory Diseases Service, DIMI, bAnesthesiology Unit, DISCAT, University of Genoa, Genoa, Italy
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: October 25, 2000
Issue release date: October 2000
Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 7
ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)
For additional information: https://www.karger.com/IAA
Abstract
Background: Mizolastine is a potent, peripherally acting, selective H1-receptor antagonist with potential anti-inflammatory properties. The aim of the study was to evaluate the in vitro effects of mizolastine on the expression of adhesion molecules by primary human airway epithelial and stromal cultures; moreover, the activity of mizolastine on parameters which reflect the immune response efficacy was investigated. Methods: Airway epithelial and stromal cells were collected from hypereosinophilic subjects by enzymatic digestion of polyps or turbinates. Cells were stimulated with interferon (IFN)-γ (500 IU/ml) in the presence of various mizolastine concentrations (6 × 10–8–6 × 10–6 M) for 24 h and the expression of CD106, CD54, CD58 and HLA class I was evaluated. Peripheral blood mononuclear cells from healthy volunteers were incubated with 1% phytohemagglutinin or anti-CD3 monoclonal antibody (20 ng/ml) in the presence of mizolastine, then T lymphocyte proliferation, HLA-DR expression and T cell subpopulations were evaluated. Results: Both in epithelial and stromal cultures, IFN-γ significantly upregulated all of the tested surface molecules (p < 0.05). The highest dose of mizolastine (6 × 10–6 M), corresponding to 10-fold the peak plasma level after a single oral administration of 10 mg, was able to act on fibroblasts, significantly downregulating the expression of CD54 (p < 0.05). Regarding T lymphocyte proliferation, the addition of mizolastine did not induce any significant change; furthermore, mizolastine was ineffective at all of the tested concentrations on both HLA-DR expression and CD4+/CD8+ ratio. Conclusions: This study demonstrated that mizolastine is able to selectively downregulate CD54 expression on stimulated stromal but not epithelial cells without impairing the immune system effectors. The possible clinical significance of these results are an antiallergic property and CD54 modulation on fibroblasts with a good safety profile as far as the lymphocyte response is concerned.
© 2000 S. Karger AG, Basel
Related Articles:
References
- Bellioni P, Catalano B, Cervellera G, Filiaci F, Mira E, Carraro A: Comparison of mizolastine with loratadine in the treatment of perennial allergic rhinitis. Rhinology 1996;34:101–104.
- Brostoff J, Fitzharris P, Dunmore C, Theron M, Blondin P: Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria. Allergy 1996;51:320–325.
-
Langer SZ, Church MK, Vargaftig BB: New Developments in the Therapy of Allergic disorders and Asthma. Basel, Karger, 1993.
- Pichat P, Angel I, Arbilla S: Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat. Arzneimittelforschung 1998;48:173–178.
- Goldhill J, Pichat P, Roome N, Angel I, Arbilla S: Effect of mizolastine on visceral sensory afferent sensitivity and inflammation during experimental colitis. Arzneimittelforschung 1998;48:179–184.
- Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA: Induction by IL-1 and interferon-gamma: Tissue distribution, biochemistry and function of a natural adherence molecule (ICAM-1). J Immunol 1986;137:245–254.
- Ciprandi G, Buscaglia S, Pesce G, Villaggio B, Bagnasco M, Canonica GW: Allergic subjects express intercellular adhesion molecule 1 (ICAM-1 or CD54) on epithelial cells of conjunctiva after allergen challenge. J Allergy Clin Immunol 1993;91:783–792.
- Ciprandi G, Ricca V, Passalacqua G, Fasolo A, Canonica GW: Intranasal fluticasone propionate reduces ICAM-1 on nasal epithelial cells both during early and late phase after allergen challenge. Clin Exp Allergy 1998;28:293–299.
- Nakajima H, Sano H, Nishimura T, Yoshida S, Iwamoto I: Role of vascular cell adhesion molecule-1/very late activation antigen-4 and intercellular adhesion molecule-1/lymphocyte function-associated antigen-1 interactions in antigen-induced eosinophil and T-cell recruitment into the tissue. J Exp Med 1994;179:1145–1154.
- Brandes LJ, Warrington RC, Arron RJ, Bogdanovic RP, Fang W, Queen GM, Stein DA, Tong J, Zaborniak CLF, LaBella F: Enhanced cancer growth in mice administered daily human-equivalent doses of some H1-antihistamines: Predictive in vitro correlates. J Natl Cancer Inst 1994;86:770–775.
- Rao VR: Binary combination effects of some pharmacologically active chemicals as promoters of tumorigenesis. J Pharm Sci 1992;81:403–407.
- Ferlazzo G, Semino C, Quartarone G, Pietra G, Melioli G: Adherent neoplastic cells grown at confluence downregulate HLA class I expression and enhance their susceptibility to lysis mediated by natural killer cells. Tissue Antigens 1997;50:459–465.
- Vignola AM, Campbell AM, Chanez P, Bousquet J, Paul-Lacoste P, Michel FB, Godard P: HLA-DR and ICAM-1 expression on bronchial epithelial cells in asthma and chronic bronchitis. Am Rev Respir Dis 1993;148:689–694.
- Bentley AM, Durham SR, Robinson DS, Menz G, Storz C, Cromwell O, Kay AB, Wardlaw AJ: Expression of endothelial and leukocyte adhesion molecules intercellular adhesion molecule-1, E-selectin and vascular cell adhesion molecule-1 in the bronchial mucosa in steady-state and allergen-induced asthma. J Allergy Clin Immunol 1993;92:857–868.
- Vignola AM, Crampette L, Mondain M, Sauvere G, Czarlewski W, Bousquet J, Campbell AM: Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy 1995;50:200–203.
- Panayi GS, Lanchbury JS, Kingsley GH: The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992;35:729–735.
- Oppenheimer-Marks N, Davis LS, Bogue DT, Ramberg J, Lipsky PE: Differential utilization of ICAM-1 and VCAM-1 during the adhesion and transendothelial migration of human T lymphocytes. J Immunol 1991;147:2913–2921.
- Canonica GW, Ciprandi G, Buscaglia S, Pesce G, Bagnasco M: The adhesion molecules of allergic inflammation: Recent insight into their functional role. Allergy 1994;49:135–141.
- Paolieri F, Battifora M, Riccio AM, Bertolini C, Cutolo M, Bloom M, Ciprandi G, Canonica GW, Bagnasco M: Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines. Ann Allergy Asthma Immunol 1998;81:601–607.
- Ciprandi G, Buscaglia S, Pesce G, Pronzato C, Ricca V, Parmiani S, Bagnasco M, Canonica GW: Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. J Allergy Clin Immunol 1995;96:971–979.
- Gleich GJ: The eosinophil and bronchial asthma: Current understanding. J Allergy Clin Immunol 1990;85:422–436.
- Pattemore PK, Johnston SL, Bardin PG: Viruses as precipitants of asthma symptoms. I. Epidemiology. Clin Exp Allergy 1992;22:325–336.
- Staunton DE, Merluzzi VJ, Rothlein R, Barton R, Marlin SD, Springer TA: A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. Cell 1989;56:849–853.
-
Jurkiewicz D: Biological effects of histamine and H1 and H2 receptors blockers. Int Rev Allergol Clin Immunol 1998;4:180–185.
Article / Publication Details
Published online: October 25, 2000
Issue release date: October 2000
Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 7
ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)
For additional information: https://www.karger.com/IAA
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
